Altrius Capital Management Inc Purchases 4,350 Shares of Pfizer Inc. (NYSE:PFE)

Altrius Capital Management Inc lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 2.9% during the third quarter, Holdings Channel reports. The firm owned 152,584 shares of the biopharmaceutical company’s stock after acquiring an additional 4,350 shares during the period. Altrius Capital Management Inc’s holdings in Pfizer were worth $4,416,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in PFE. China Universal Asset Management Co. Ltd. bought a new stake in Pfizer in the first quarter worth about $315,000. Dorsey & Whitney Trust CO LLC raised its position in Pfizer by 16.0% in the first quarter. Dorsey & Whitney Trust CO LLC now owns 72,467 shares of the biopharmaceutical company’s stock worth $2,011,000 after acquiring an additional 9,989 shares during the period. Forum Financial Management LP raised its position in Pfizer by 1.8% in the first quarter. Forum Financial Management LP now owns 57,342 shares of the biopharmaceutical company’s stock worth $1,591,000 after acquiring an additional 1,033 shares during the period. M&G Plc bought a new stake in Pfizer in the first quarter worth about $19,885,000. Finally, Poehling Capital Management INC. raised its position in shares of Pfizer by 9.3% in the first quarter. Poehling Capital Management INC. now owns 54,416 shares of the biopharmaceutical company’s stock valued at $1,510,000 after purchasing an additional 4,609 shares during the period. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the topic of several research reports. StockNews.com raised shares of Pfizer from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Sanford C. Bernstein assumed coverage on shares of Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective for the company. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. UBS Group boosted their price objective on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Finally, Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and an average price target of $32.92.

Pfizer Trading Down 3.2 %

NYSE PFE traded down $0.82 during trading on Friday, hitting $25.20. The company had a trading volume of 48,698,549 shares, compared to its average volume of 37,839,766. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a market cap of $142.81 billion, a price-to-earnings ratio of 33.37, a price-to-earnings-growth ratio of 0.85 and a beta of 0.67. The company’s fifty day moving average is $28.71 and its 200-day moving average is $28.65.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. During the same period in the prior year, the business earned ($0.17) EPS. The company’s revenue for the quarter was up 31.2% on a year-over-year basis. On average, sell-side analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 6.67%. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. This represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.